Budesonide and formoterol fumarate dihydrate

(Symbicort)

Budesonide and formoterol fumarate dihydrate

Drug updated on 11/28/2023

Dosage FormInhalation (oral; budesonide/formoterol; 80 or 60 mcg/4.5 mcg)
Drug ClassMultiple
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For treatment of asthma in patients 6 years of age and older.
  • For maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema.

Product Monograph / Prescribing Information

Document TitleYearSource
Symbicort (budesonide and formoterol fumarate dihydrate) Prescribing Information.2019AstraZeneca Dunkerque Production, Dunkerque, France

Randomized Controlled Trials

Clinical Practice Guidelines